Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

NCT05643118 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

GENETIC: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)

Sponsor

Olix Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]